Chapter 35: Women’s Health Drugs – Hormones, Contraceptives & Fertility

Key medication classes discussed include estrogens and progestins, which are utilized for hormone therapy (HT) to manage menopause symptoms, treat hormone deficiencies (hypogonadism), prevent pregnancy (in contraceptives), and serve as palliative treatments for certain cancers. The clinical usage of HT remains controversial, particularly for older individuals, with modern guidelines advocating for individualized risk assessments following findings from the Women’s Health Initiative studies. Contraceptive drugs (often estrogen-progestin combinations) primarily prevent conception by inhibiting ovulation and altering uterine mucous. The text also covers medication for bone health, focusing on drugs for osteoporosis—a condition characterized by progressive bone density loss common post-menopause. Treatment strategies include bisphosphonates (like alendronate), which inhibit bone breakdown by osteoclasts; Selective Estrogen Receptor Modulators (SERMs) (like raloxifene); and anabolic agents like teriparatide, which stimulates bone formation. Furthermore, drugs affecting uterine motility are detailed: oxytocics (like oxytocin and dinoprostone) stimulate uterine contractions to induce labor or prevent postpartum hemorrhage, while tocolytics temporarily halt preterm labor. Specialized pharmacological treatments include fertility drugs, such as menotropins, to induce ovulation in infertile persons, and hormones used in gender-affirming care (feminizing hormone therapy). Throughout these topics, the nursing process emphasizes thorough assessment for contraindications (such as thromboembolic disorders or estrogen-dependent cancers), careful monitoring of adverse effects (like the risk of esophageal erosion with bisphosphonates), and specific patient education regarding compliance, sun exposure, and drug interactions (e.g., antibiotics reducing contraceptive efficacy).